Prior to examination, please amend the above-identified application as follows:

In the Claims:

Please cancel Claim 19 without prejudice or disclaimer as drawn to a non-elected invention.

REMARKS

Claims 1 - 17 are pending. Claim 19 has been canceled without prejudice or disclaimer as it is directed to a non-elected invention. An Appendix of Pending Claims is attached for the Examiner's convenience.

Applicants submit that inventorship has not been changed by the cancellation of Claim 19.

Attached hereto is a marked-up version of the changes made to the claims by this Amendment. The attached page is captioned **"Version with Markings to Show Changes Made"**.

The Examiner is invited to contact the undersigned at (415) 781-1989 if any issues may be resolved in that manner.

Respectfully submitted,

DORSEY & WHITNEY LLP,

Dated: 1/22/03

Four Embarcadero Center
Suite 3400
San Francisco, California 94111-4187
Telephone: (415) 781-1989
Fax No. (415) 398-3249

By: _____
Renee M. Kosslak, Reg. No 47,717
for Robin M. Silva, Reg. No. 38,304
Filed under 37 C.F.R. § 1.34(a)

Claim 19 has been cancelled.

Appendix of Pending Claims

1. A method for modulating the immunogenicity of a target protein, said method comprising:

    a) inputting a protein backbone structure with variable residue positions of a target protein into a computer;

    b) computationally generating a set of primary variant amino acid sequences; and,

    c) applying a computational immunogenicity filter against said set to identify at least one candidate variant protein.

2. A method according to claim 1 further comprising testing said candidate variant protein to determine if said immunogenicity is altered relative to said target protein.

3. A method according to claim 1 further comprising classifying each variable residue position as either a core, surface or boundary residue.

4. A method according to claim 1 wherein said computationally generating step comprises a DEE computation.

5. A method according to claim 4 wherein said DEE computation is selected from the group consisting of original DEE and Goldstein DEE.

6. A method according to claim 1 wherein said set of primary variant amino acid sequences are optimized for at least one scoring function.

7. A method according to claim 6 wherein said set of primary variant amino sequences optimized for at least one scoring function comprises the globally optimal protein sequence.

8. (Amended) A method according to claim 6 wherein said scoring function is selected from the group consisting of a van der Waals potential scoring function, a hydrogen bond potential scoring function, an atomic salvation scoring function, an electrostatic scoring function and a secondary structure propensity scoring function.

1102644_1.DOC

9. A method according to claim 1 wherein said computationally generating step includes the use of a Monte Carlo search.

10. A method according to claim 1 wherein said target protein is from a non human species and said candidate variant protein exhibits reduced immunogenicity in humans.

11. A method according to claim 1 wherein the immunogenicity of said candidate variant protein is reduced relative to said target protein.

12. A method according to claim 1 wherein said candidate variant protein is non-immunogenic.

13. A method according to claim 11 or 12 wherein said candidate variant protein is more stable than said target protein.

14. A method according to claim 1 wherein said modulating the immunogenicity of said target protein comprises modifying the amino acid sequence that binds to an MHC molecule.

15. A method according to claim 14 wherein said MHC molecule belongs to MHC class I.

16. A method according to claim 14 wherein said MHC molecule belongs to MHC class II.

17. A method according to claim 1 wherein said modulating the immunogenicity of said target protein comprises modifying an amino acid sequence encoding a T cell epitope.